CASI Pharmaceuticals Inc.
CASIF Healthcare Biotechnology
CASI Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.7 million, down 27.4% from fiscal 2024. In the quarter to December 2025, revenue fell 45.9%, EPS grew 54.4%, free cash flow fell 23,251.7% and total debt rose 6.97%, each against the same quarter a year earlier.
Follow CASIF
CASI Pharmaceuticals Inc. (CASIF) P/E ratio
CASI Pharmaceuticals Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| 25 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| AEON AEON Biopharma, Inc. compare | n/m |
| ALLR Allarity Therapeutics, Inc. compare | n/m |
| PLUR Pluri Inc. compare | n/m |
| ENSC Ensysce Biosciences, Inc. compare | n/m |
| INAB IN8bio, Inc. compare | n/m |
| CASIF CASI Pharmaceuticals Inc. | n/m |
| ASBP Aspire-Lakewood Holdings, Inc. compare | 0.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)